Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant collagen
- Development stage
- Phase 4
- Lead developer
- FibroGen
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal, Topical, Implantation
01
Overview
Recombinant collagen is a biotechnologically produced form of collagen, used in various biomedical applications, including tissue engineering, drug delivery systems, and cosmetic medicine. It is produced through recombinant DNA technology, allowing for the creation of collagen without the risks associated with animal-derived sources. Recombinant collagen can be used as a skin booster, injected intradermally to enhance skin quality, and in wound healing and orthopedic applications.
- Brand names
- SkinColla
- Other names
- recombinant human collagenrecombinant humanized collagen
02
Targets
Dermal extracellular matrix collagenNeuraminidase
Beyond the preview
Go deeper on recombinant collagen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant collagen.